Benralizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Benralizumab is a type of medicine called a monoclonal antibody that is made in the research
clinic; it works by blocking a specific protein in the body called interleukin-5. The study
medicine, benralizumab, is not yet approved for doctors to treat patients with EGPA. It is
considered an experimental drug in this study.